193 related articles for article (PubMed ID: 26139550)
1. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
[TBL] [Abstract][Full Text] [Related]
2. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
Mirault T; Rea D; Azarine A; Messas E
Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
[TBL] [Abstract][Full Text] [Related]
3. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
4. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
5. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
[TBL] [Abstract][Full Text] [Related]
6. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
7. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.
Giles FJ; Mauro MJ; Hong F; Ortmann CE; McNeill C; Woodman RC; Hochhaus A; le Coutre PD; Saglio G
Leukemia; 2013 Jun; 27(6):1310-5. PubMed ID: 23459450
[TBL] [Abstract][Full Text] [Related]
8. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
9. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment.
Nagai T; Karakawa M; Komine M; Muroi K; Ohtsuki M; Ozawa K
Eur J Haematol; 2013 Sep; 91(3):270-272. PubMed ID: 23734955
[TBL] [Abstract][Full Text] [Related]
10. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Caocci G; Mulas O; Capodanno I; Bonifacio M; Annunziata M; Galimberti S; Luciano L; Tiribelli M; Martino B; Castagnetti F; Binotto G; Pregno P; Stagno F; Abruzzese E; Bocchia M; Gozzini A; Albano F; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; Baratè C; De Gregorio F; Stella R; Gugliotta G; Pirillo F; Trawinska MM; Sicuranza A; Cattaneo D; Attolico I; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
Ann Hematol; 2021 Aug; 100(8):2005-2014. PubMed ID: 33388860
[TBL] [Abstract][Full Text] [Related]
12. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
Caocci G; Mulas O; Bonifacio M; Abruzzese E; Galimberti S; Orlandi EM; Iurlo A; Annunziata M; Luciano L; Castagnetti F; Gozzini A; Stagno F; Binotto G; Pregno P; Albano F; Martino B; Fozza C; Scaffidi L; Trawinska MM; Baratè C; Elena C; Cattaneo D; Scalzulli E; La Nasa G; Foà R; Breccia M
Int J Cardiol; 2019 Aug; 288():124-127. PubMed ID: 31029498
[TBL] [Abstract][Full Text] [Related]
13. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study.
Levato L; Cantaffa R; Kropp MG; Magro D; Piro E; Molica S
Eur J Haematol; 2013 Jun; 90(6):531-2. PubMed ID: 23506097
[No Abstract] [Full Text] [Related]
14. Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke.
Kakadia B; Thakkar R; Sanborn E; Suero-Abreu GA; Jovin TG; Then R
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105883. PubMed ID: 34090174
[TBL] [Abstract][Full Text] [Related]
15. Progressive cardiovascular disease in a patient under treatment with nilotinib.
Roa-Chamorro R; Torres-Quintero L; García de Los Ríos C; Puerta-Puerta JM; González-Bustos P; Mediavilla-García JD
Clin Investig Arterioscler; 2020; 32(2):66-69. PubMed ID: 31280877
[TBL] [Abstract][Full Text] [Related]
16. Acute ischemic intestinal necrosis as a rare side effect of nilotinib.
Li L; Liu W; Zeng Z; Chen S
Niger J Clin Pract; 2019 Jan; 22(1):131-133. PubMed ID: 30666032
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia.
Tokatlı M; Ismayilov R; Erkin Çınar O; Haznedaroğlu İC
Turk J Haematol; 2024 Mar; 41(1):59-60. PubMed ID: 38153228
[No Abstract] [Full Text] [Related]
18. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
Minson AG; Cummins K; Fox L; Costello B; Yeung D; Cleary R; Forsyth C; Tatarczuch M; Burbury K; Motorna O; Shortt J; Fleming S; McQuillan A; Schwarer A; Harrup R; Holmes A; Ratnasingam S; Chan KL; Hsu WH; Ashraf A; Putt F; Grigg A
Blood Adv; 2019 Apr; 3(7):1084-1091. PubMed ID: 30944100
[TBL] [Abstract][Full Text] [Related]
19. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
